Muscarinic Acetylcholine Receptor M2 (CHRM2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Muscarinic Acetylcholine Receptor M2 (CHRM2) is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, thalamus, lungs, and prostate. An increase in M2 receptors has been associated with depression.

The CHRM2 pipeline market research report provides comprehensive information on the CHRM2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research, and development history as well as the latest news and press releases. Additionally, the report provides an overview of key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects.

Key Therapy Areas in the CHRM2 Pipeline Products Market

The key therapy areas in the CHRM2 pipeline products market are the central nervous system, respiratory, genito urinary system & sex hormones, cardiovascular, dermatology, and genetic disorders.

CHRM2 Pipeline Products Market Analysis by Therapy Areas

CHRM2 Pipeline Products Market Analysis by Therapy Areas

For more therapy area insights, download a free report sample

Key Mechanisms of Action in the CHRM2 Pipeline Products Market

The key mechanisms of action in the CHRM2 pipeline products market are Muscarinic Acetylcholine Receptor M2 Antagonist and Muscarinic Acetylcholine Receptor M2 Agonist.

CHRM2 Pipeline Products Market Analysis by Mechanisms of Action

CHRM2 Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the CHRM2 Pipeline Products Market

The key routes of administration in the CHRM2 pipeline products market are oral, intravenous, and transdermal.

CHRM2 Pipeline Products Market Analysis by Routes of Administration

CHRM2 Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the CHRM2 Pipeline Products Market

The key molecule type in the CHRM2 pipeline product market is small molecule.

Major Companies in the CHRM2 Pipeline Products Market

The major companies in the CHRM2 pipeline products market are Anavex Life Sciences Corp, Apnimed Inc, Dermavant Sciences Inc, Karuna Therapeutics Inc, Sinsin Pharmaceutical Co Ltd, TheraVida Inc, and Trigone Pharma Ltd.

CHRM2 Pipeline Products Market Analysis by Companies

CHRM2 Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

CHRM2 Pipeline Products Market Report Overview

Key Therapy Areas Central Nervous System, Respiratory, Genito Urinary System & Sex Hormones, Cardiovascular, Dermatology, and Genetic Disorders
Key Mechanisms of Action Muscarinic Acetylcholine Receptor M2 Antagonist and Muscarinic Acetylcholine Receptor M2 Agonist
Key Routes of Administration Oral, Intravenous, and Transdermal
Key Molecule Type Small Molecule
Major Companies Anavex Life Sciences Corp, Apnimed Inc, Dermavant Sciences Inc, Karuna Therapeutics Inc, Sinsin Pharmaceutical Co Ltd, TheraVida Inc, and Trigone Pharma Ltd

Scope

  • The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)
  • The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities
  • The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Anavex Life Sciences Corp
Apnimed Inc
Dermavant Sciences Inc
Karuna Therapeutics Inc
Sinsin Pharmaceutical Co Ltd
TheraVida Inc
Trigone Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M2 (CHRM2) – Overview

Muscarinic Acetylcholine Receptor M2 (CHRM2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M2 (CHRM2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M2 (CHRM2) – Companies Involved in Therapeutics Development

Anavex Life Sciences Corp

Apnimed Inc

Dermavant Sciences Inc

Karuna Therapeutics Inc

Sinsin Pharmaceutical Co Ltd

TheraVida Inc

Trigone Pharma Ltd

Muscarinic Acetylcholine Receptor M2 (CHRM2) – Drug Profiles

(atomoxetine + oxybutynin) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(lidocaine + oxybutynin) SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

(oxybutynin + pilocarpine) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(oxybutynin + reboxetine) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(pilocarpine + tolterodine) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(trospium chloride + xanomeline) – Drug Profile

Product Description

Mechanism Of Action

History of Events

AD-109 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ANAVEX-141 – Drug Profile

Product Description

Mechanism Of Action

History of Events

blarcamesine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

oxybutynin – Drug Profile

Product Description

Mechanism Of Action

Muscarinic Acetylcholine Receptor M2 (CHRM2) – Dormant Products

Muscarinic Acetylcholine Receptor M2 (CHRM2) – Discontinued Products

Muscarinic Acetylcholine Receptor M2 (CHRM2) – Product Development Milestones

Featured News & Press Releases

May 18, 2022: Karuna Therapeutics to host virtual event highlighting clinical program for psychosis in Alzheimer’s disease

Mar 15, 2022: Anavex Life Sciences announces presentation of phase 2 clinical biomarker data from Anavex 2-73-PDD-001 Parkinson’s disease dementia study at AD/PD™ 2022 International Conference

Mar 09, 2022: Apnimed study APC-004 phase 2 data to be presented at World Sleep 2022

Feb 04, 2022: Anavex life sciences provides supplemental information on ANAVEX 2-73 (blarcamesine) AVATAR Phase 3 trial for the treatment of adult patients with Rett syndrome

Feb 01, 2022: ANAVEX 2-73 (Blarcamesine) AVATAR phase 3 trial met primary and secondary efficacy endpoints

Dec 16, 2021: Apnimed announces dosing of first patient in phase 3 MARIPOSA confirmatory trial of AD504, a potential nighttime oral treatment for Obstructive Sleep Apnea (OSA)

Oct 13, 2021: Anavex Life Sciences reports data review by the independent DSMB reported for phase 2b/3 trial of ANAVEX 2-73 for AD

Oct 13, 2021: Apnimed announces positive phase 2 (Study APC-003) data demonstrating durability-of-effect and improved quality-of-life in patients with obstructive sleep apnea after investigational AD109 treatment

Oct 13, 2021: Apnimed announces positive phase 2 data (Study APC-004) demonstrating improvement in measures of obstructive sleep apnea and a dose-response with AD109, an oral pharmacologic investigational treatment for the disease

Sep 13, 2021: Novamind to serve as research site for Karuna Therapeutics late-stage clinical trial

Aug 26, 2021: Anavex Life Sciences announces publication of Foundational data for ANAVEX2-73 (blarcamesine) in Fragile X syndrome (Autism)

Aug 13, 2021: Trigone Pharma announces the initiation of a phase 2 clinical trial of TRG-100 in patients with interstitial cystitis/bladder pain syndrome

Jul 29, 2021: Anavex Life Sciences announces ANAVEX2-73 (Blarcamesine) significantly prevented Aß (Abeta)-induced cognitive deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease

Jul 22, 2021: Trigone Pharma to present preclinical data for TRG-100 in interstitial cystitis / bladder pain syndrome at the upcoming American Urological Association Conference (AUA) in September 2021

Jun 29, 2021: Anavex reports positive data from Parkinson’s disease dementia study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Anavex Life Sciences Corp, 2022

Pipeline by Apnimed Inc, 2022

Pipeline by Dermavant Sciences Inc, 2022

Pipeline by Karuna Therapeutics Inc, 2022

Pipeline by Sinsin Pharmaceutical Co Ltd, 2022

Pipeline by TheraVida Inc, 2022

Pipeline by Trigone Pharma Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Frequently asked questions

Muscarinic Acetylcholine Receptor M2 (CHRM2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Muscarinic Acetylcholine Receptor M2 (CHRM2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Muscarinic Acetylcholine Receptor M2 (CHRM2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Muscarinic Acetylcholine Receptor M2 (CHRM2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.